101-PGC-005 is Type IA prodrug of dexamethasone that targets CD206+ macrophages.

In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).

The submission to treat PsO is for children aged 6 years and up while the jPsA submission is to treat children aged 5 years and older.

If approved, SL1009 has the potential to be the first approved medication for PDCD, and would be available as an oral solution.

Colleen Sloan, PA-C, RDN, unpacks the essential nutrient children are missing in their diets and how providers and parents can start implementing.

Colleen Sloan, PA-C, RDN, details how technology can affect eye health in children and identifies which nutrients can help mitigate its effect.

Mike Hennessy Jr. shares his thoughts on the holiday health paradox.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Practicing gratitude boosts wellbeing, improves sleep, and reduces stress. Parents can foster it daily by modeling gratitude, helping others, and reflecting on positives.

The most common reactions reported were the following: irritability or fussiness (30.1%), local reactions (21.1%) and fever (13.8%).

Results demonstrated that slowed aperiodic activity was present in brain areas linked to concussion symptoms such as impaired concentration and memory.

A recent study suggests the ketogenic diet could positively impact menstrual cycles by boosting ketones, potentially unlocking new therapeutic insights for women’s reproductive health.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

Reportedly, the child experienced mild symptoms and has received flu antivirals.

A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.

Currently, there are no treatments for the serious, rare pediatric disease.

From 2017-2018, antiviral treatment of hospitalized children with influenza ranged from 70%-86%. In the 2023-2024 season, it was less than 60%.

Once-daily icotrokinra versus placebo demonstrated clinically significant skin clearance in those with moderate-to-severe plaque psoriasis.

A further understanding of the role SARS-CoV-2 plays in T2D incidence can add an important component to benefit and risk considerations to prevent COVID-19.

Results demonstrated that daily oral infigratinib treatment led to increases in annualized height velocity and improvement in body proportionality.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

With this expanded FDA clearance, the wearable becomes the first FDA-cleared, non-drug therapy to treat acute migraines in children.

The application indication is for adults and pediatric patients aged 12 years and older with CSU whose disease is not adequately controlled with H1 antihistamines.

With the decision, Kebilidi becomes the first FDA-approved gene therapy for AADC deficiency, and is indicated for adult and pediatric patients.

A target action date for potential approval of prademagene zamikeracel (pz-cel) has been set for April 29, 2025.